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Abstract
AIM
To understand the influence of chronic kidney disease 
(CKD) on mortality, need for transfusion and rebleeding 
in gastrointestinal (GI) bleeding patients.
METHODS
A systematic search was conducted in three databases 
for studies on GI bleeding patients with CKD or end-
stage renal disease (ESRD) with data on outcomes 
of mortality, transfusion requirement, rebleeding rate 
and length of hospitalization (LOH). Calculations were 
performed with Comprehensive Meta-Analysis software 
using the random effects model. Heterogeneity was 
tested by using Cochrane’s Q and I 2 statistics. Mean 
difference (MD) and OR (odds ratio) were calculated.
RESULTS
1063 articles (EMBASE: 589; PubMed: 459; Cochrane: 
15) were found in total. 5 retrospective articles and 1 
prospective study were available for analysis. These 6 
articles contained data on 406035 patients, of whom 
51315 had impaired renal function. The analysis showed 
a higher mortality in the CKD group (OR = 1.786, 
95%CI: 1.689-1.888, P  < 0.001) and the ESRD group 
(OR = 2.530, 95%CI: 1.386-4.616, P  = 0.002), and a 
rebleeding rate (OR = 2.510, 95%CI: 1.521-4.144, P  
< 0.001) in patients with impaired renal function. CKD 
patients required more unit red blood cell transfusion 
(MD = 1.863, 95%CI: 0.812-2.915, P  < 0.001) and 
spent more time in hospital (MD = 13.245, 95%CI: 
6.886-19.623, P  < 0.001) than the controls.
CONCLUSION
ESRD increases mortality, need for transfusion, 
rebleeding rate and LOH among GI bleeding patients. 
Prospective patient registries and observational clinical 
trials are crucially needed.  
Key words: Gastrointestinal bleeding; Chronic kidney 
disease; Mortality; Blood transfusion; Rebleeding
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Acute gastrointestinal bleeding is a potentially 
life-threatening abdominal emergency that remains a 
common cause of hospitalization. Pre-existing chronic 
kidney disease (CKD) may worsen the prognosis. This 
is the first meta-analysis to compare CKD patients and 
normal renal function patients based on GI bleeding. 
We investigated these two groups in terms of mortality, 
transfusion amount, rebleeding rate and length of 
hospitalization.
Hágendorn R, Farkas N, Vincze Á, Gyöngyi Z, Csupor D, Bajor 
J, Erőss B, Csécsei P, Vasas A, Szakács Z, Szapáry L, Hegyi 
P, Mikó A. Chronic kidney disease severely deteriorates the 
outcome of gastrointestinal bleeding: A meta-analysis. World J 
Gastroenterol 2017; 23(47): 8415-8425  Available from: URL: 
http://www.wjgnet.com/1007-9327/full/v23/i47/8415.htm  DOI: 
http://dx.doi.org/10.3748/wjg.v23.i47.8415
INTRODUCTION
Acute gastrointestinal bleeding (GI) is an abdominal 
emergency which remains a common cause of 
hospitalization[1]. An accurate diagnosis of GI bleeding 
relies on prompt resuscitation, initial risk evaluation, 
and provisional clinical diagnosis followed by an 
appropriate definitive investigation which enables 
specific therapeutic interventions. GI bleeding involves 
any bleeding in the GI tract from the esophagus, 
stomach, small intestines or large intestines to the 
anus.
Upper GI bleeding has an annual incidence that 
ranges from 40 to 150 episodes per 100000 persons 
and a morality rate of 6%-10%[2], whereas lower GI 
bleeding has an annual incidence ranging from 20 to 
27 episodes per 100000 persons and a mortality rate 
of 4%-10%[3,4]. Since GI bleeding is a potentially life-
threatening acute disorder, understanding the risk 
factors that worsen the disease is of great importance. 
Scoring systems have therefore been developed to 
predict the outcome of therapy. The Rockall score 
is one of these scoring systems. It includes pre-
endoscopic (age, shock and comorbidity) and post-
endoscopic (diagnosis and presence or absence of 
endoscopic stigmata of recent haemorrhage) factors[5]. 
Several studies have demonstrated high mortality with 
higher Rockall scores[6]. However, Laeeq et al[7] have 
not found significantly higher mortality in patients with 
high pre-endoscopic Rockall score (> 5). The Rockall 
score only assesses the risk of mortality in patients 
with upper GI bleeding. The Glasgow Blatchford 
score is another scoring system which uses clinical 
and laboratory parameters. Neither scoring system 
makes distinction between pre-existing renal failure 
and acute renal failure due to haemorrhage. Both 
of these scoring systems have been designed for 
the risk assessment of upper GI bleeding. Previous 
studies have shown evidence of increased risk of GI 
bleeding in chronic kidney disease (CKD) patients 
and with end-stage renal disease (ESRD) requiring 
renal replacement therapy in comparison with the 
general population, but also an association with higher 
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mortality[8-10]. Further studies have demonstrated that 
bleeding in CKD patients from the upper GI tract is 
more common than from the lower GI tract[11]. The 
increased prevalence of small bowel erosions, ulcers 
and angioectasias is also well known in CKD patients 
and it may be as high as 33% and it often causes 
obscure gastrointestinal bleeding[12-14]. However, no 
meta-analyses or systematic reviews have been 
conducted to assess the difference between CKD/ESRD 
patients and the normal renal function population with 
regard to GI bleeding.
The aim of this study was therefore to examine 
outcomes of GI bleeding, such as mortality, blood 
transfusion requirement, rebleeding rate and length of 
hospitalization (LOH) in CKD/ESRD patients compared 
to patients with normal renal functions.
MATERIALS AND METHODS
Search strategy
This study was conducted using the preferred 
reporting items for systematic review and meta-
analysis protocols (PRISMA-P)[15]. It was registered 
in the international prospective register of systematic 
reviews, PROSPERO (under registration number 
CRD42017077987). The meta-analysis was based 
on the PICO (Patient, Intervention, Comparison, 
Outcome) format (P: patients with GI bleeding; I: 
chronic renal failure; C: normal renal function; O: 
mortality, blood transfusion, rebleeding). A systematic 
search was performed in 3 databases, Pubmed, 
EMBASE and the Cochrane Library, with the following 
terms: (“GI bleeding” OR “gastrointestinal bleeding” 
OR “gastrointestinal hemorrhage”) AND (“chronic 
renal failure” OR “uremia” OR “chronic kidney failure”). 
The search was limited to human data and to full-
text English-language articles if appropriate. The 
exact search term in Pubmed was: [“GI bleeding”
(All Fields) OR “gastrointestinal bleeding”(All Fields) 
OR “gastrointestinal hemorrhage”(All Fields)] AND 
[“chronic renal failure”(All Fields) OR “uraemia”
(All Fields) OR “uremia”(MeSH Terms) OR “uremia”
(All Fields) OR “chronic kidney failure”(All Fields)] 
AND [“humans”(MeSH Terms) AND English(lang)]. 
The database search was conducted up to 10 March 
2017. Reference management software (EndNote 
X7) was used to remove duplicates by searching 
overlaps between titles, authors and publication years. 
The reference lists in the articles obtained were also 
checked, and one more eligible publication was found.
Study selection
The studies were selected separately by two inves-
tigators (RH and AM). Disagreements were resolved 
by consulting a third reviewer (PH). Clinical studies 
were eligible provided they reported data on adult 
patients hospitalized with upper or lower GI bleeding 
grouped into normal renal function and CKD or ESRD 
groups. Articles were eligible containing data of CKD/
ESRD patients and a control group in the same study. 
Information on mortality, transfusion, rebleeding and 
length of hospitalization (LOH) was manually searched. 
Case reports, conference abstracts, reviews and 
studies on paediatric patients up to age 18 alone were 
excluded. We found a high number of articles in which 
the risk of GI bleeding in CKD patients was studied, 
but they were not eligible for our meta-analysis, as 
there were no data available on outcomes of the GI 
bleeding in a control population without CKD/ESRD.
Data extraction, synthesis and analysis
Mortality data, number of transfused blood units, 
rebleeding and length of hospitalization data were 
extracted to analyse the influence of CKD and/or 
ESRD on the outcome of GI bleeding. In Sood et al[9], 
Tsai et al[16] and Boyle et al[17], the number of patients 
was calculated from percentages of mortality. Boyle 
et al[17] supplied information on transfusion in mean 
and standard error of mean, for which statistical 
calculation standard deviation (SD) was computed. 
Tsai et al[16] reported data from transfusions in the 
median and interquartile range (IQR), from which 
mean and SD were calculated with Hozo’s method[18]. 
All meta-analytic calculations were performed with 
Comprehensive Meta-Analysis software (Version 
3.0, Biostat Inc.) using the random effects model 
(DerSimonian-Laird method[19]). Odds ratios (OR) 
and 95% confidence intervals (CI) were calculated for 
binary outcomes. In the case of LOH and transfusion 
for comparing mean data, a mean difference (MD) 
with 95%CI was calculated. All analyses were two-
tailed, with an α of 0.05.
Heterogeneity was tested using Cochrane’s Q and 
the I2 statistics. Based on the Cochrane Handbook, 
I2 = 100% × (Q - df)/Q, with I2 representing 
the magnitude of the heterogeneity (moderate: 
30%-60%; substantial: 50%-90%; considerable: 
75%-100%)[20]. Only results that were available from 
at least 3 studies were displayed graphically with 
forest plots. We performed a sensitivity analysis to 
assess whether removing any study result in different 
interpretation and final conclusion[21]. To assess the 
effect of the year of publication on the outcome data 
we performed meta-regression analysis. We calculated 
the regression coefficient and interpreted the data with 
their 95%CI and r-analog.
Quality of studies and risk of bias
Because of the low number of eligible articles, 
publication bias was obtained with a visual inspection 
of the funnel plots alone according to the Cochrane 
Handbook[20]. The Newcastle-Ottawa Scale (NOS) 
adjusted to our study design was used[22] to assess 
the quality of nonrandomized cohort studies. The 
8417 December 21, 2017|Volume 23|Issue 47|WJG|www.wjgnet.com
Hágendorn R et al . GI bleeding and chronic kidney disease
8418 December 21, 2017|Volume 23|Issue 47|WJG|www.wjgnet.com
included in the analysis reported in Alvarez et al[24], 
so we did not use the data in that publication. The 
remaining 5[9,16,17,25,26] and one other[10] eligible record 
which was found in reference lists were included in 
the meta-analysis. The basic characteristics of the 6 
eligible articles in the meta-analysis are shown in Table 
2. These 6 publications contained data on 406,035 
patients, of whom 51315 had impaired renal function 
parameters and 354720 had normal renal functions. 
2 articles contained data on patients with CKD and 
4 on ESRD patients. There were 2 studies involving 
CKD and ESRD patients, with their group identified as 
the CKD mixed group. The number of ESRD patients 
analysed was 15201, the CKD group had 36035 
members, and 79 patients could be classified in the 
CKD mixed group.
Mortality
Data on mortality was available in all of the articles 
included, but Zuckerman et al[26] reported no mortality 
data for the control group; we therefore removed it 
from the statistical analysis. Hung et al[25] reported 
mortality data from a 6-wk follow-up period, while the 
other articles contained data on an unknown follow-up 
period. In the subgroup analysis for CKD and ESRD, 
a higher mortality rate was detected compared to 
the control population (CKD: OR = 1.786, 95%CI: 
1.689-1.888, P < 0.001; ESRD: OR = 2.530, 95%CI: 
1.386-4.616, P = 0.002, Figure 2).
Required units for transfusion
4 studies reported data on the transfused units of red 
blood cells. The required transfusion was 1.8 times 
higher in the patients with abnormal renal function (MD 
selection, comparability and outcome data were 
assessed based on 6 items (Table 1) with the “star 
system”: high-quality items with a low risk of bias 
received one star, while low-quality items with a high 
or unknown risk of bias were assigned no stars. 3 
items were included during the selection process. In 
the case of representativeness in the study population, 
we assigned a star if all of the GI bleeding patients 
with normal or impaired renal function were included. 
If any selection criteria applied, we assigned no points. 
We used the classical definition of CKD[23], which 
characterizes the disease with a glomerular filtration 
rate (GFR) < 60 m/min lasting longer than 3 mo. 
ESRD was defined as a condition where haemodialysis 
or chronic peritoneal dialysis is performed for at least 
3 mo. With regard to outcome, only the follow-up time 
for rebleeding was rated in articles that provided this 
information. Assessment of outcome and length of 
follow-up were not rated because most of the articles 
were retrospective.  
RESULTS
Study selection
1063 articles (EMBASE: 589; PubMed: 459; Cochrane: 
15) were found altogether through database searches. 
The flowchart (Figure 1) shows the study selection 
strategy. Studies in our meta-analysis were dated 
from 1946 to 2017. After removing duplicates, 875 
publications remained. Following initial screening 
based on titles and abstracts, 23 articles were 
retrieved and screened. A further 18 were excluded 
because of missing outcome data or a missing control 
group. Patients with acute renal failure were also 
Table 1  Modified Newcastle-Ottawa Scale criteria
Adapted Newcastle-Ottawa Scale Items High-quality items carrying a low risk of bias 
(green)
Low-quality items carrying a high (red) or an 
unknown (yellow) risk of bias
Item 1: Representativeness of the initial study 
population - patients with GI bleeding and CKD/
ESRD
All patients with upper or lower GI bleeding and 
CKD/ESRD were included.
Low: any selection criteria were applied to the 
study population (e.g., only transplanted patients).
Unknown: no data on selection process.
Item 2: Representativeness of the initial study 
population - patients with GI bleeding without 
CKD/ESRD
All patients with upper or lower GI bleeding 
without CKD/ESRD included.
Low: any selection criteria were applied to the 
study population.
Unknown: no data on selection process.
Item 3: Ascertainment of exposure We defined chronic renal failure as present when 
eGFR was < 60 mL/min at least 3 mo. We defined 
end-stage renal disease as a condition where 
hemodialysis or chronic peritoneal dialysis is 
performed at least for 3 mo.
Low: CKD or ESRD is not present in all of the 
patients.
Unknown: no definitions of the conditions 
mentioned are provided.
Item 4: Comparability of cohorts A Study controls for age: no significant difference 
was detected.
Low: significant difference was detected.
Unknown: no statement.
Item 5: Comparability of cohorts B Study controls for taking ulcerogenic drugs: no 
significant difference was detected
Low: significant difference was detected between 
taking ulcerogenic drugs.
Unknown: no comparison made by taking 
ulcerogenic drugs.
Item 6: Follow-up time for rebleeding The follow-up time is clearly defined. Low: incomplete follow-up
Unknown: no follow-up time is mentioned.
CKD: Chronic kidney disease; ESRD: End-stage renal disease.
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= 1.863, 95%CI: 0.812-2.915, P < 0.001, Figure 3). 
Rebleeding rate
It was possible to retrieve data on the rebleeding 
rate from 3 articles, but Cheung et al[10] contained 
simultaneous data from the CKD and ESDR groups, 
which could be analysed. Boyle et al[17]. also presented 
data on rebleeding. However, this included cases of 
uncontrolled bleeding, so we excluded these data from 
our analysis. We found that patients with impaired 
renal function tend to bleed again 2.5 more times 
than patients with normal renal function (OR = 2.510, 
95%CI: 1.521-4.144, P < 0.001, Figure 4).
Length of hospitalization
Two of the six articles included reported hospital stay 
outcomes. Patients with impaired renal function spent 
significantly more time in hospital after GI bleeding (MD 
= 13.245, 95%CI: 6.886-19.623, P < 0.001, Figure 5).
Heterogeneity and quality assessment of data
High heterogeneity was detected for mortality in the 
ESRD group (Q = 17.082; DF = 3; I2 = 82.438%; P 
< 0.001), while the heterogeneity for CKD was low 
(Q = 1.767; DF = 2; I2 = 0%; P = 0.413). However, 
a low heterogeneity was detected for the transfusion 
requirements (Q = 3.448; DF = 3; I2 = 13.003%; P 
= 0.328), the rebleeding rate (Q = 3.328; DF = 3; 
I2 = 9.845%; P = 0.344) and LOH (Q = 1.100; DF 
= 2; I2 = 0%; P = 0.577). To ascertain publication 
bias, we only made a visual assessment of the funnel 
plot (Figure 6) because we were only able to include 
6 studies in our meta-analysis. Sensitivity analysis 
showed no significant difference in the OR of mortality, 
by removing any of the articles (Supplementary Figure 
1). Meta-regression showed slight significance, in the 
Records indentified through database 
searching 
(n  = 1063)
Additional records identified through 
other sources 
(n  = 1)
Records after duplicates removed 
(n  = 875)
Records screened 
(n  = 875)
Records excluded 
(n  = 852)
Full-text articles assessed for eligibility 
(n  = 23)
Studies included in qualitative 
synthesis (n  = 6)
In
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Studies included in quantitative 
synthesis 
(meta-analysis) 
(n  = 6)
Full-text articles excluded 
with reasons 
(n  = 17)
Figure 1  Flowchart of the study selection procedure.
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most recent articles the OR is decreasing with the 
time (regression coefficient: b = -0.0548; 95%CI: 
-0.0968 to -0.0128; P = 0.0105; r-analog: 0.2, 
Supplementary Figure 2A). The number of required 
units for transfusion has not changed since the 1980s 
(b = -0.0028; 95%CI: -0.0242 to -0.0186; P = 0.7972; 
r-analog: 0.00, Supplementary Figure 2B). Based on 
data from 4 articles, no difference in rebleeding rate 
could be observed in the last 30 years (b = 0.0027; 
95%CI: -0.0353 to 0.03; P = 0.8726; r-analog: 0.00, 
Supplementary Figure 2C). 
On the score based on the Newcastle-Ottawa 
Scale, articles were assigned between 2 and 6 stars 
out of a maximum of 6 stars (Table 3). There was 
a low risk of bias in representativeness in the study 
and the control population; it received 100% (Figure 
7). With regard to ascertaining exposure, 33% of 
the articles represented a low risk of bias, while 66% 
had an unclear risk of bias. In these articles CKD and 
ESRD were not clearly defined, or patients were sorted 
based on a code system. With regard to a comparison 
of age, half of the articles contained no clear data on 
Table 2  Basic characteristics of the studies included in the meta-analysis
Ref. Country Study type Years of study Group Sample size Age Mortality Transfusion Rebleeding Length of 
hospitalization
Boyle et al[17], 1983 United 
States
Retrospective 1977-1981 Control 40 54 ± 21 √ √ - √
CKD (mix) 20 59 ± 41
Cheung et al[10], 2010 Canada Retrospective 2000-2006 Control 50 67 ± 13 √ √ √ √
CKD 50 71 ± 13
ESRD 50 68 ± 12
Hung et al[25], 2014 Taiwan Retrospective 2007 Control 6322 54.6 ± 13.3 √ - - -
ESRD 110 NR
Sood et al[9], 2012 United 
States
Retrospective 2007 Control 347245 NR √ - - -
CKD 35985 NR
ESRD 14983 NR
Tsai et al[16], 1996 Taiwan Prospective 1991-1994 Control 640 55.7 ± 16.22 √ √ √ -
ESRD 58 64.1 ± 11.42
Zuckerman et al[26], 1985 United 
States
Retrospective 1980-1983 Control 423 63 (16-96)3 - - √ -
CKD (mix) 59 57 (24-84)3
1Data expressed as mean ± SEM (standard error of mean); 2Data expressed as mean ± SD (standard deviation); 3Data expressed as median (interquartile 
range). NR: Not reported; CKD: Chronic kidney disease; ESRD: End-stage renal disease.
Table 3  Stars based on the Modified Newcastle-Ottawa Scale
Ref. Item 1 Item 2 Item 3 Item 4 Item 5 Item 6 Total (*)
Boyle et al[17], 1983 * * - * * 4
Cheung et al[10], 2010 * * * * * * 6
Hung et al[25], 2014 * * - - - 2
Sood et al[9], 2012 * * - - - 2
Tsai et al[16], 1996 * * * - * - 4
Zuckerman et al[26], 1985 * * - - - * 3
Figure 2  Forest plot representing the differences in mortality in gastrointestinal bleeding patients with normal and impaired renal function. Size of squares 
for risk ratio reflects weight of trial in pooled analysis. Horizontal bars represent 95%CI. CKD: Chronic kidney disease; ESRD: End-stage renal disease.
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Study name Subgroup within study Statistics for each study Dead/Total Odds ratio and 95%CI Risk of bias
Odds 
ratio
Lower 
limit
Upper 
limit
P  value Renal failure Control
Sood et al  2012 CKD 1.782 1.685 1.885 0.000 1511/35985 8334/347245
Boyle et al  1983 CKD (mix) 3.083 0.618 15.390 0.170 4/20 3/40
Cheung et al  2010 CKD 4.571 0.919 22.730 0.063 8/50 2/50
CKD 1.786 1.689 1.888 0.000 1523/36055 8339/347335
Hung et al  2014 ESRD 1.190 0.793 1.786 0.401
Sood et al  2012 ESRD 2.276 2.112 2.452 0.000 794/14983 8334/347245
Cheung et al  2010 ESRD 4.571 0.919 22.730 0.063 8/50 2/50
Tsai et al  1996 ESRD 7.717 3.055 19.493 0.000 8/58 13/640
ESRD 2.530 1.386 4.616 0.002 810/15091 8349/347935
Favours CKD/ESRD favours control
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the groups and there was a significant difference in the 
ages of the ESRD and control groups in Tsai et al[16]. 
50% of the articles reported data on taking ulcerogenic 
drugs; the other half represented an unclear risk of 
bias. The follow-up time for rebleeding was analysed in 
3 articles; only one did not report this clearly.
DISCUSSION
CKD is a term that covers all degrees of decreased renal 
function (mild, moderate, and severe chronic kidney 
disease), where the GFR is lower than 60 mL/min for 
longer than 3 mo[23]. CKD is a worldwide public health 
problem, with both incidence and prevalence rising 
and the main causes being diabetes mellitus and high 
blood pressure. ESRD patients requiring haemodialysis 
or peritoneal dialysis 3 times a week represent a high 
burden and cost for the health care system. As the 
prevalence of hypertension and diabetes mellitus, the 
most important etiological factors for CKD and ESRD is 
increasing worldwide, we predict that GI bleeding with 
CKD will be a growing problem. According to Ohmori 
et al[13] the number of patients on hemodyalisis has 
tripled between 1990 and 2010. This is the first meta-
analysis to report on the severity of complications after 
GI bleeding in patients with CKD or ESRD and normal 
renal function groups. Based on a systematic search in 
3 databases, we were able to include 6 articles, which 
contained data on 406035 patients, of whom 51315 
had impaired renal function. A higher prevalence of 
peptic ulcers was reported among ESRD patients 
undergoing long-term dialysis[27,28]. The elevated risk 
Study name Subgroup within study Statistics for each study Difference in means 
and 95%CI
Risk of bias
Difference in means Lower limit Upper limit P  value
Cheung et al  2010 CKD -1.200 -2.515 0.115 0.074
Tsai et al  1996 ESRD -1.670 -3.708 0.368 0.108
Cheung et al  2010 ESRD -2.700 -4.614 -0.786 0.006
Boly et al  1983 CKD (mix) -5.300 -10.436 -0.164 0.043
-1.863 -2.915 -0.812 0.001
Favours CKD/ESRD favours control
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Figure 3  Forest plot representing the required units of transfusion in gastrointestinal bleeding patients with normal and impaired renal function. Size of 
squares for the difference in standardized mean values reflects weight of trial in pooled analysis. Horizontal bars represent 95%CI. CKD: Chronic kidney disease; 
ESRD: End-stage renal disease.
Study name Subgroup within study Outcome Statistics for each study Exposed/Total Odds ratio and 95%CI Risk of bias
Odds 
ratio
Lower 
limit
Upper 
limit
P  value Cases Controls
Cheung et al  2010 CKD Rebleeding 1.194 0.371 3.841 0.766 7/50 6/50
Tsai et al  1996 ESRD Rebleeding 1.691 0.487 5.869 0.408 3/58 20/640
Zuckerman et al  1985 CKD (mix) Rebleeding 2.864 1.476 5.555 0.002 15/59 45/423
Cheung et al  2010 ESRD Rebleeding 4.495 1.610 12.545 0.004 19/50 6/50
2.510 1.521 4.144 0.000 44/217 77/1163
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Figure 4  Forest plot representing the rebleeding rate in gastrointestinal bleeding patients with normal and impaired renal function. Size of squares for risk 
ratio reflects weight of trial in pooled analysis. Horizontal bars represent 95%CI. CKD: Chronic kidney disease; ESRD: End-stage renal disease.
Study name Subgroup within study Statistics for each study Difference in means 
and 95%CI
Risk of bias
Difference in means Lower limit Upper limit P  value
Cheung et al  2010 CKD -8.400 -20.020 3.220 0.157
Boyle et al  1983 CKD (mix) -14.300 -23.636 -4.964 0.003
Cheung et al  2010 ESRD -17.400 -30.556 -4.244 0.010
-13.254 -19.623 -6.886 0.000
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Figure 5  Forest plot representing the differences in length of hospitalization in gastrointestinal bleeding patients with normal and impaired renal function. 
Size of squares for the difference in standardized mean values reflects weight of trial in pooled analysis. Horizontal bars represent 95%CI. CKD: Chronic kidney 
disease; ESRD: End-stage renal disease.
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for GI bleeding in CKD and ESRD patients is also 
well known[29]. The most frequent causes of lower 
GI bleeding in this population have been described; 
diverticulosis, haemorrhoids, and ischaemic colitis have 
been identified in addition to angioectasias[30], but no 
cohort study has been conducted on this topic yet. 
Although we did not intend to narrow our search to 
upper GI bleeding, the articles eligible for our inclusion 
criteria contained data only on patients with upper 
GI bleeding, and no studies with lower GI bleeding 
met our inclusion criteria. Only a few of the studies 
detailed the endoscopic findings and cause of bleeding. 
Cheung et al[10] included only peptic ulcer bleeding 
patients, while the study of Hung et al[25] examined 
only esophageal variceal bleeding. Tsai et al[16] found 
that erosive gastritis was significantly higher in ESRD 
group, while Boyle et al[17] saw gastric ulcer as the 
most common cause of bleeding in the impaired renal 
function group, but it was not significant compared to 
controls. Zuckerman et al[26] found significantly more 
angiodysplasia and erosive esophagitis in the impaired 
renal function group.
Based on the pooled data, we found that ESRD 
increases mortality 2.5 times while CKD increases 
it 1.8 times in GI bleeding compared to the controls 
with normal renal function, but these ORs are not 
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Figure 6  Funnel plot. A: Funnel plot of mortality; B: Funnel plot of required transfusion; and C: Funnel plot of rebleeding.
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significantly different. Weng et al[31] reported that ESRD 
patients admitted with primary upper GI bleeding have 
a profoundly increased risk of in-hospital mortality. 
Using a large multi-centre database, Sood et al[9] 
reported that the in-hospital mortality risk is 50% 
higher in CKD patients and 3 times greater in ESRD 
patients. Holden et al[32] reported that the incidence 
rate of major bleeding episodes in haemodialyzed 
patients was 2.5% per person-year and that use of 
aspirin and/or warfarin increased this risk. Based on 
the result of the meta-regression the mortality-rate of 
GI bleeding has improved since the 1980s. It is likely 
one of the reasons for the heterogeneity of the data. 
Inhomogen patient groups also result in a significant 
bias. However the sensitivity analysis showed that none 
of the articles influences significantly the pooled OR.
Cardiovascular disease, current smoking[33] and 
even haemostasis disorders[34] may play a role in the 
background of higher risk for GI bleeding in ESRD 
patients. Unfortunately only few of the analysed 
articles detailed the other comorbidities of the GI 
bleeding patients. In the article of Cheung et al[10]. 
there was no significant difference in the comorbidities 
between ESRD, CKD and normal renal function 
group. More people in CKD and ESRD groups suffered 
from hypertension, diabetes mellitus and platelet 
abnormalities in the study of Sood et al[9], while the 
cirrhosis was less common than in controls. Volume 
replacement and blood transfusion are important 
parts of the therapy of GI bleeding. This meta-analysis 
demonstrated that patients with chronic impaired renal 
function develop 2.5 times more rebleeding episodes 
and require almost 2 more red blood cell units for 
transfusion than the control group. Patients with 
impaired renal function spent more time in hospital 
than the control group.
There are several limitations to this study; the-
refore, the results of this meta-analysis should be 
regarded with caution. Unfortunately, only a low 
number of articles was found on this topic, with half 
of them written in the 1980s and 1990s. In the recent 
articles, CKD and ESRD groups were separated, but 
in the earlier publications these groups were mixed, 
leading to a bias in our analysis, and the definition of 
GFR was also not mentioned. The diagnosis was based 
on elevated creatinine level. Hung et al[25] only involved 
patients with cirrhosis and the mortality rate was 
monitored up to 6 wk, while hospital mortalities were 
presumably included in the other articles. Publications 
with rebleeding data did not follow patients for the 
same time interval, and 1 paper did not report on the 
follow-up time. The strength of this meta-analysis is 
the high number of patients. 
Our results have demonstrated that patients with 
ESRD show higher mortality during GI bleeding. CKD 
patients require more transfusion, and the rebleeding 
rate is also more elevated than that in patients with 
normal renal function. Because of these severe con-
ditions, the LOH is also longer. Patients with ESRD or 
CKD should be observed more carefully due to the 
elevated complication rate. In this meta-analysis we 
wanted to highlight the importance of this clinical 
problem and we believe that it needs further scientific 
research. In order to understand the effect of CKD/
ESRD and other comorbidities on the outcomes of 
GI bleeding in more details, observational trials, and 
registries on GI bleeding should be developed. 
ARTICLE HIGHLIGHTS
Research background
Chronic kidney disease is a significant comorbidity, which can worsen the 
outcomes of gastrointestinal (GI) bleeding. 
Research motivation
We wanted to understand the role of chronic kidney disease (CKD) and end-
stage renal disease (ESRD) in the natural history of GI bleeding.
Research objectives
Our goal was to investigate the influence of CKD and ESRD on the outcomes 
of GI bleeding, based on all available data published in this topic. 
Research methods
A comprehensive search was carried out in PubMed, Embase and Cochrane 
Library databases for studies detailing the outcomes of GI bleeding in the 
context of kidney functions. We used the PRISMA P protocol, registered our 
project through PROSPERO and assessed the quality of the included articles 
by using the Newcastle-Ottawa Scale, to ensure that this meta-analysis is done 
to the highest possible standards. The statistical calculations were performed 
with Comprehensive Meta-Analysis software, using the random effects model 
(DerSimonian-Laird method).
Research results
In this analysis 51315 patients with CKD and 354720 controls were included 
(6 articles). We found that the mortality of GI bleeding was significantly worse 
in CKD and ESRD with an OR of 1.79 and 2.53 respectively. Patients with 
kidney disease needed significantly more transfusion with a MD of 1.86 and 
the rebleeding rate was significantly worse in the group with impaired kidney 
function with an OR of 2.51. Patients with impaired kidney function needed 
significantly longer hospitalization with a MD of 13.25.
Research conclusions
This is the first meta-analysis and systematic review in this topic, which 
quantifies kidney disease as a negative risk factor in GI bleeding. GI bleeding 
in patients with chronic renal failure significantly increases the mortality rate, 
rebleeding rate, length of hospitalization, and require more blood transfusion 
compared to patients with normal kidney functions. Kidney disease significantly 
worsens the outlook of patients presenting with GI bleeding. Patients with 
chronic kidney disease will need to be treated with more caution due to the 
worse outcomes of GI bleeding. Close monitoring of the fluid balance and 
kidney functions, careful fluid therapy and prevention of acute kidney injury in 
these patients may improve the outcomes of GI bleeding.
Research perspectives
Although CKD, ESRD, and other comorbidities are major risk factors for 
unfavorable outcomes in GI bleeding, their roles are not well investigated nor 
understood and they need further scrutiny. We would better understand the 
role of CKD in ESRD in GI bleeding from analysis of extensive data from large 
multicenter and multinational observational studies and registries accurately 
recording the outcomes and the kidney functions.
 ARTICLE HIGHLIGHTS
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